Canada communicable disease report = Releve des maladies transmissibles au Canada最新文献

{"title":"Thematic description of factors linked with extended-spectrum beta-lactamase-producing Enterobacteriaceae in humans.","authors":"Jamie Goltz, Carl Uhland, Sydney Pearce, Colleen Murphy, Carolee Carson, Jane Parmley","doi":"10.14745/ccdr.v50i06a04","DOIUrl":"10.14745/ccdr.v50i06a04","url":null,"abstract":"<p><strong>Background: </strong>Extended-spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae are associated with serious antimicrobial-resistant infections in Canadians. Humans are exposed to ESBL-producing Enterobacteriaceae through many interconnected pathways. To better protect Canadians, it is important to generate an understanding of which sources and activities contribute most to ESBL exposure and infection pathways in Canada.</p><p><strong>Objective: </strong>The aims of this scoping review were to thematically describe factors potentially associated with ESBL-producing Enterobacteriaceae colonization, carriage and/or infection in humans from countries with a very high human development index and describe the study characteristics.</p><p><strong>Methods: </strong>Four databases (PubMed, CAB Direct, Web of Science, EBSCOhost) were searched to retrieve potentially relevant studies. Articles were screened for inclusion, and factors were identified, grouped thematically and described.</p><p><strong>Results: </strong>The review identified 381 relevant articles. Factors were grouped into 13 themes: antimicrobial use, animals, comorbidities and symptoms, community, demographics, diet and substance use, health care, household, occupation, prior ESBL colonization/carriage/infection, residential care, travel, and other. The most common themes reported were demographics, health care, antibiotic use and comorbidities and symptoms. Most articles reported factors in hospital settings (86%) and evaluated factors for ESBL-producing Enterobacteriaceae infections (52%).</p><p><strong>Conclusion: </strong>This scoping review provided valuable information about which factor themes have been well described (e.g., health care) and which have been explored less frequently (e.g., diet or animal contact). Themes identified spanned human, animal and environmental contexts and settings, supporting the need for a diversity of perspectives and a multisectoral approach to mitigating exposure to antimicrobial resistance.</p>","PeriodicalId":94304,"journal":{"name":"Canada communicable disease report = Releve des maladies transmissibles au Canada","volume":"50 6","pages":"211-222"},"PeriodicalIF":0.0,"publicationDate":"2024-06-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11251730/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141636391","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy, effectiveness and immunogenicity of reduced HPV vaccination schedules: A review of available evidence.","authors":"Joshua Montroy, Marina I Salvadori, Nicole Forbes, Vinita Dubey, Sarah Almasri, Anna Jirovec, Cathy Yan, Katarina Gusic, Adrienne Stevens, Kelsey Young, Matthew Tunis","doi":"10.14745/ccdr.v50i06a01","DOIUrl":"10.14745/ccdr.v50i06a01","url":null,"abstract":"<p><strong>Background: </strong>Current National Advisory Committee on Immunization (NACI) guidance recommends human papillomavirus (HPV) vaccines be administered as a two or three-dose schedule. Recently, several large clinical trials have reported the clinical benefit of a single HPV vaccine dose. As a result, the World Health Organization released updated guidance on HPV vaccines in 2022, recommending a two-dose schedule for individuals aged 9-20 years, and acknowledging the use of an alternative off-label single dose schedule.</p><p><strong>Objective: </strong>The objective of this overview is to provide a detailed account of the available evidence comparing HPV vaccination schedules, which was considered by NACI when updating recommendations on HPV vaccines.</p><p><strong>Methods: </strong>To identify relevant evidence, existing systematic reviews were leveraged where possible. Individual studies were critically appraised, and the Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology was used to assess the certainty of evidence.</p><p><strong>Results: </strong>Available evidence suggests that a one, two, or three-dose HPV vaccine schedule may provide similar protection from HPV infection. While antibody levels against HPV vaccine types were statistically significantly lower with a single dose schedule compared to two or three doses, titres were sustained for up to 16 years. The clinical significance of lower antibody titres is unknown, as there is no established immunologic correlate of protection.</p><p><strong>Conclusion: </strong>While the available evidence on single-dose HPV vaccination schedules shows a one-dose schedule is highly effective, continued follow-up of single-dose cohorts will be critical to understanding the relative duration of protection for reduced dose schedules and informing future NACI guidance on HPV vaccines.</p>","PeriodicalId":94304,"journal":{"name":"Canada communicable disease report = Releve des maladies transmissibles au Canada","volume":"50 6","pages":"166-178"},"PeriodicalIF":0.0,"publicationDate":"2024-06-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11251446/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141636390","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Outbreak of Human Trichinellosis - Arizona, Minnesota, and South Dakota, 2022.","authors":"Shama Cash-Goldwasser, Dustin Ortbahn, Muthu Narayan, Conor Fitzgerald, Keila Maldonado, James Currie, Anne Straily, Sarah Sapp, Henry S Bishop, Billy Watson, Margaret Neja, Yvonne Qvarnstrom, David M Berman, Sarah Y Park, Kirk Smith, Stacy Holzbauer","doi":"10.14745/ccdr.v50i05a05","DOIUrl":"10.14745/ccdr.v50i05a05","url":null,"abstract":"<p><p>Trichinellosis is a parasitic zoonotic disease transmitted through the consumption of meat from animals infected with <i>Trichinella</i> spp. nematodes. In North America, human trichinellosis is rare and is most commonly acquired through consumption of wild game meat. In July 2022, a hospitalized patient with suspected trichinellosis was reported to the Minnesota Department of Health. One week before symptom onset, the patient and eight other persons shared a meal that included bear meat that had been frozen for 45 days before being grilled and served rare with vegetables that had been cooked with the meat. Investigation identified six trichinellosis cases, including two in persons who consumed only the vegetables. Motile <i>Trichinella</i> larvae were found in remaining bear meat that had been frozen for >15 weeks. Molecular testing identified larvae from the bear meat as <i>Trichinella nativa</i>, a freeze-resistant species. Persons who consume meat from wild game animals should be aware that that adequate cooking is the only reliable way to kill <i>Trichinella</i> parasites and that infected meat can cross-contaminate other foods.</p>","PeriodicalId":94304,"journal":{"name":"Canada communicable disease report = Releve des maladies transmissibles au Canada","volume":"50 5","pages":"153-157"},"PeriodicalIF":0.0,"publicationDate":"2024-05-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11149922/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141249282","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of the COVID-19 pandemic on inbound air travel to Canada.","authors":"Vanessa Gabriele-Rivet, Erin Rees, Afnan Rahman, Rachael M Milwid","doi":"10.14745/ccdr.v50i34a04","DOIUrl":"10.14745/ccdr.v50i34a04","url":null,"abstract":"<p><strong>Background: </strong>Commercial air travel can result in global dispersal of infectious diseases. During the coronavirus disease 2019 (COVID-19) pandemic, many countries implemented border measures, including restrictions on air travel, to reduce the importation risk of COVID-19. In the context of inbound air travel to Canada, this study aimed to: 1) characterize travel trends before and during the pandemic, and 2) statistically assess the association between travel volumes and travel restrictions during the pandemic.</p><p><strong>Methods: </strong>Monthly commercial air travel volume data from March 2017 to February 2023 were obtained from the International Air Transport Association (IATA). National and airport-level travel trends to Canada were characterized by inbound travel volumes, the number of countries contributing travellers and the ranking of the top ten countries contributing travellers across the study period, by six year-length subperiod groupings (three pre-pandemic and three pandemic). Using seasonal autoregressive integrated moving average (SARIMA) models, interrupted time series (ITS) analyses assessed the association between major travel restrictions and travel volumes by including variables to represent changes to the level and slope of the time series.</p><p><strong>Results: </strong>The pre-pandemic inbound travel volume increased by 3% to 7% between consecutive subperiods, with three seasonal peaks (July-August, December-January, March). At the onset of the pandemic, travel volume decreased by 90%, with the number of contributing countries declining from approximately 200 to 140, followed by a slow recovery in volume and seasonality. A disruption in the ranking of countries that contributed travellers was also noticeable during the pandemic. Results from the ITS analysis aligned with the timing of travel restrictions as follows: implementation in March 2020 coincided with a sharp reduction in volumes, while the easing of major restrictions, starting with the authorization of fully vaccinated travellers from the United States to enter Canada in August 2021, coincided with an increase in the slope of travel volumes. Descriptive and statistical results suggest a near-return of pre-pandemic travel patterns by the end of the study period.</p><p><strong>Conclusion: </strong>Study results suggest resilience in commercial air travel into Canada. Although the COVID-19 pandemic led to a disruption in travel trends, easing of travel restrictions appeared to enable pre-pandemic trends to re-emerge. Understanding trends in air travel volumes, as demonstrated here, can provide information that supports preparedness and response regarding importation risk of infectious pathogens.</p>","PeriodicalId":94304,"journal":{"name":"Canada communicable disease report = Releve des maladies transmissibles au Canada","volume":"50 3-4","pages":"106-113"},"PeriodicalIF":0.0,"publicationDate":"2024-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11090504/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140917565","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Innovations in public health surveillance: An overview of novel use of data and analytic methods.","authors":"Heather Rilkoff, Shannon Struck, Chelsea Ziegler, Laura Faye, Dana Paquette, David Buckeridge","doi":"10.14745/ccdr.v50i34a02","DOIUrl":"10.14745/ccdr.v50i34a02","url":null,"abstract":"<p><p>Innovative data sources and methods for public health surveillance (PHS) have evolved rapidly over the past 10 years, suggesting the need for a closer look at the scientific maturity, feasibility, and utility of use in real-world situations. This article provides an overview of recent innovations in PHS, including data from social media, internet search engines, the Internet of Things (IoT), wastewater surveillance, participatory surveillance, artificial intelligence (AI), and nowcasting. Examples identified suggest that novel data sources and analytic methods have the potential to strengthen PHS by improving disease estimates, promoting early warning for disease outbreaks, and generating additional and/or more timely information for public health action. For example, wastewater surveillance has re-emerged as a practical tool for early detection of the coronavirus disease 2019 (COVID-19) and other pathogens, and AI is increasingly used to process large amounts of digital data. Challenges to implementing novel methods include lack of scientific maturity, limited examples of implementation in real-world public health settings, privacy and security risks, and health equity implications. Improving data governance, developing clear policies for the use of AI technologies, and public health workforce development are important next steps towards advancing the use of innovation in PHS.</p>","PeriodicalId":94304,"journal":{"name":"Canada communicable disease report = Releve des maladies transmissibles au Canada","volume":"50 3-4","pages":"93-101"},"PeriodicalIF":0.0,"publicationDate":"2024-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11075801/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140878331","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Commentary on the adoption of a test-based versus syndromic-based approach to outbreak declaration and management in hospital and institutional settings.","authors":"Patrick Galange, Richard Mather, Barbara Yaffe, Michael Whelan, Michelle Murti","doi":"10.14745/ccdr.v50i34a03","DOIUrl":"10.14745/ccdr.v50i34a03","url":null,"abstract":"<p><p>At present, Ontario, like most other jurisdictions in Canada, uses a syndromic-based surveillance definition for acute respiratory infection (ARI) outbreaks in institutions and public hospitals. Confirmed outbreaks are defined as either two or more ARIs in 48 hours with any common epidemiological link and at least one that is laboratory-confirmed; or three cases of ARIs occurring within 48 hours with any common epidemiological link, and not necessarily with lab confirmation. However, with the adoption of broader test-based approaches for sick patients/residents throughout the pandemic, new challenges have surfaced regarding the declaration and management of ARI outbreaks with a variety of scenarios in respiratory testing results. Decisions, including the determination of epidemiological linkage when there are discordant/negative test results, have become more complicated with the addition of virus-specific test results for every sick individual. The ARI outbreak case definition and management guidance was updated in 2018. The purpose of this commentary is to highlight epidemiological trends in ARI outbreaks in Ontario over the 2022-2023 season compared to the 2018-2019 and 2019-2020 pre-pandemic seasons. This is followed by a discussion around some of the benefits and challenges of implementing a test-based versus syndromic-based approach to ARI outbreaks.</p>","PeriodicalId":94304,"journal":{"name":"Canada communicable disease report = Releve des maladies transmissibles au Canada","volume":"50 3-4","pages":"102-105"},"PeriodicalIF":0.0,"publicationDate":"2024-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11090474/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140917562","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Microbiology of bloodstream infections in Ontario, Canada during COVID-19 pandemic.","authors":"Mohammad R Hasan, Yasmeen M Vincent, Daniela Leto, Huda Almohri","doi":"10.14745/ccdr.v50i34a05","DOIUrl":"10.14745/ccdr.v50i34a05","url":null,"abstract":"<p><strong>Background: </strong>Bloodstream infections (BSI) caused by a wide range of bacterial and fungal pathogens are associated with high rates of morbidity and mortality. Based on an estimate in 2017, the number of BSI incidences in Ontario is 150 per 100,000 population. The epidemiology of BSIs may be affected by many factors, including the social and travel restrictions and increased rates of hospitalizations in Ontario during the coronavirus disease 2019 (COVID-19) pandemic.</p><p><strong>Objectives: </strong>This study aimed to assess the changes in the microbiology of BSIs in Ontario during the COVID-19 pandemic compared to the pre-pandemic period.</p><p><strong>Methods: </strong>Retrospective blood culture data (n=189,106) from LifeLabs Ontario (July 2018 to December 2021) were analyzed. Blood culture positivity rates for common bacterial pathogens were compared between pre-COVID-19 (July 2018 to March 2020) and COVID-19 (April 2020 to December 2021) periods in community and hospital settings, using the chi-square test for significance.</p><p><strong>Results: </strong>During the COVID-19 period, blood culture positivity rates in the community remained the same, while hospital rates increased by approximately threefold (<i>p</i>=0.00E-00). In the community, the isolation rates of most bacterial species remained unchanged, except for an increase in <i>Enterococcus</i> spp. and a decrease in <i>Salmonella</i> spp. The rates of antibiotic-resistant organisms (AROs) also significantly decreased in the community. In hospitals, all bacterial species, including AROs, showed significant increases in isolation rates during the COVID-19 period.</p><p><strong>Conclusion: </strong>The study revealed shifts in the microbiology of BSIs and suggests changes in the epidemiology of BSIs during the COVID-19 pandemic in Ontario, both in hospitals and in the community.</p>","PeriodicalId":94304,"journal":{"name":"Canada communicable disease report = Releve des maladies transmissibles au Canada","volume":"50 3-4","pages":"114-118"},"PeriodicalIF":0.0,"publicationDate":"2024-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11090503/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140917568","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Summary of the National Advisory Committee on Immunization (NACI) Updated Guidance on Influenza Vaccination During Pregnancy.","authors":"Winnie Siu, Angela Sinilaite, Jesse Papenburg","doi":"10.14745/ccdr.v50i34a01","DOIUrl":"10.14745/ccdr.v50i34a01","url":null,"abstract":"<p><strong>Background: </strong>Seasonal influenza infection can lead to serious complications and adverse outcomes for pregnant individuals, the developing fetus and infants younger than six months of age. This supplemental statement provides an evidence summary on the safety and effectiveness of influenza vaccination in pregnant individuals, and the benefits and risks to the pregnant person, the developing fetus and infants younger than six months of age.</p><p><strong>Methods: </strong>A systematic review was conducted on the effectiveness and safety of influenza vaccination in pregnancy. The National Advisory Committee on Immunization (NACI)'s evidence-based process was used to assess the quality of eligible studies, summarize and analyze the findings, and apply an ethics, equity, feasibility and acceptability lens to develop recommendations.</p><p><strong>Results: </strong>The evidence suggests that influenza vaccination during pregnancy is effective in reducing the risk of laboratory-confirmed influenza infection and hospitalization in both pregnant individuals and their infants up to six months postpartum. The evidence also suggests that influenza vaccination during pregnancy does not increase the risk of non-obstetric serious adverse events in pregnant persons, infant death, spontaneous abortion, stillbirth, preterm birth, small for gestational age, low birth weight and congenital anomalies.</p><p><strong>Conclusion: </strong>Based on this body of evidence, NACI reaffirms the safety and importance of influenza vaccination during pregnancy. NACI recommends that individuals at any stage of pregnancy should receive an age-appropriate inactivated, unadjuvanted or recombinant influenza vaccine each influenza season. Influenza vaccination may be given at the same time as, or at any time before or after administration of another vaccine, including the coronavirus disease 2019 (COVID-19) or pertussis vaccines.</p>","PeriodicalId":94304,"journal":{"name":"Canada communicable disease report = Releve des maladies transmissibles au Canada","volume":"50 3-4","pages":"86-92"},"PeriodicalIF":0.0,"publicationDate":"2024-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11073834/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140878332","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Epidemiological characteristics of human infections with avian influenza A(H5N6) virus, China and Laos: A multiple case descriptive analysis, February 2014-June 2023.","authors":"Simran Sandhu, Christina Ferrante, Aaron MacCosham, Nicole Atchessi, Christina Bancej","doi":"10.14745/ccdr.v50i12a09","DOIUrl":"https://doi.org/10.14745/ccdr.v50i12a09","url":null,"abstract":"<p><strong>Background: </strong>The first human infection with highly pathogenic avian influenza A(H5N6) virus was reported in 2014. From then until June 30, 2023, 85 human cases with confirmed A(H5N6) infection have been reported worldwide.</p><p><strong>Objective: </strong>To address the present gap in knowledge of the overall epidemiology of human A(H5N6) infections, the epidemiological characteristics of human infection with A(H5N6) in China from February 2014 to June 2023 are described.</p><p><strong>Methods: </strong>Considering the severity of human infections with A(H5N6) virus (case fatality rate: 39%), the increased frequency of case reports from 2021 to present day, and lack of comprehensive epidemiologic analysis of all cases, we conducted a multiple-case descriptive analysis and a literature review to create an epidemiologic profile of reported human cases. Case data was obtained via a literature search and using official intelligence sources captured by the Public Health Agency of Canada's International Monitoring and Assessment Tool (IMAT), including Event Information Site posts from the World Health Organization.</p><p><strong>Results: </strong>Most human A(H5N6) cases have been reported from China (China: 84; Laos: 1), with severe health outcomes, including hospitalization and death, reported among at-risk populations. The majority (84%) of cases reported contact with birds prior to illness onset. Cases were detected throughout the course of the year, with a slight decrease in illness incidence in the warmer months.</p><p><strong>Conclusion: </strong>As A(H5N6) continues to circulate and cause severe illness, surveillance and prompt information sharing is important for creating and implementing effective public health measures to reduce the likelihood of additional human infections.</p>","PeriodicalId":94304,"journal":{"name":"Canada communicable disease report = Releve des maladies transmissibles au Canada","volume":"50 1-2","pages":"77-85"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11037882/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140871868","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Burden of disease of respiratory syncytial virus in infants, young children and pregnant women and people.","authors":"Elissa M Abrams, Pamela Doyon-Plourde, Phaedra Davis, Nicholas Brousseau, Andrea Irwin, Winnie Siu, April Killikelly","doi":"10.14745/ccdr.v50i12a01","DOIUrl":"10.14745/ccdr.v50i12a01","url":null,"abstract":"<p><strong>Background: </strong>Passive immunization products for infants and pregnant women and people have sparked interest in understanding Canada's respiratory syncytial virus (RSV) burden. This rapid review examines RSV burden of disease in infants, young children and pregnant women and people.</p><p><strong>Methods: </strong>Electronic databases were searched to identify studies and systematic reviews reporting data on outpatient visits, hospitalizations, intensive care unit admissions, deaths and preterm labour associated with RSV. We also contacted Canadian respiratory virus surveillance experts for additional data.</p><p><strong>Results: </strong>Overall, 17 studies on infants and young children and 10 studies on pregnant women and people were included, in addition to primary surveillance data from one Canadian territory (Yukon). There were higher rates of medical utilization for infants than older children. Hospitalization rates were highest in infants under six months (more than 1% annually), with 5% needing intensive care unit admission, but mortality was low. Severe outcomes often occurred in healthy full-term infants and burden was higher than influenza. Respiratory syncytial virus attack rate was 10%-13% among pregnant women and people. Only one study found a higher hospitalization rate in pregnant women and people compared to non-pregnant women and people. Limited evidence was found on intensive care unit admission, death and preterm birth for pregnant women and people.</p><p><strong>Conclusion: </strong>While risk of severe outcomes is larger in high-risk infants and children, healthcare burden is greatest in healthy term infants. The RSV severity for pregnant women and people appears to be similar to that for non-pregnant women and people.</p>","PeriodicalId":94304,"journal":{"name":"Canada communicable disease report = Releve des maladies transmissibles au Canada","volume":"50 1-2","pages":"1-15"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10949905/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140178720","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}